Corcept Therapeutics (CORT) is set to announce its Q4 earnings on Tuesday afternoon. The company missed revenue expectations last quarter but the market anticipates a 36.3% year-over-year revenue growth for Q4. Analysts have reconfirmed their estimates, although Corcept has a history of missing revenue targets and its stock has underperformed recently compared to peers like Eli Lilly and Bristol-Myers Squibb.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Corcept (CORT) Q4 Earnings: What To Expect
Corcept Therapeutics (CORT) is set to announce its Q4 earnings on Tuesday afternoon. The company missed revenue expectations last quarter but the market anticipates a 36.3% year-over-year revenue growth for Q4. Analysts have reconfirmed their estimates, although Corcept has a history of missing revenue targets and its stock has underperformed recently compared to peers like Eli Lilly and Bristol-Myers Squibb.